Johnson & Johnson (NYSE:JNJ) PT Raised to $196.00 at Raymond James

Johnson & Johnson (NYSE:JNJGet Rating) had its price objective raised by stock analysts at Raymond James from $195.00 to $196.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Raymond James’ price target suggests a potential upside of 7.06% from the company’s previous close.

Other research analysts have also issued research reports about the stock. Bank of America began coverage on shares of Johnson & Johnson in a research note on Wednesday, March 2nd. They set a “neutral” rating for the company. The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and increased their target price for the stock from $180.00 to $183.00 in a research note on Wednesday, March 16th. Citigroup increased their target price on shares of Johnson & Johnson from $203.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Morgan Stanley reduced their price target on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $188.57.

Shares of JNJ opened at $183.08 on Wednesday. The company has a current ratio of 1.35, a quick ratio of 1.12 and a debt-to-equity ratio of 0.41. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $185.94. The firm has a 50-day moving average price of $172.73 and a 200 day moving average price of $168.12. The firm has a market capitalization of $481.37 billion, a P/E ratio of 23.44, a P/E/G ratio of 2.71 and a beta of 0.72.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.61 by $0.06. Johnson & Johnson had a net margin of 22.26% and a return on equity of 37.46%. The firm had revenue of $23.43 billion during the quarter, compared to analyst estimates of $23.62 billion. During the same quarter in the prior year, the firm posted $2.59 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.0% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 10.48 earnings per share for the current fiscal year.

In related news, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total value of $4,173,776.25. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.35% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the business. McElhenny Sheffield Capital Management LLC boosted its position in shares of Johnson & Johnson by 1.8% during the 1st quarter. McElhenny Sheffield Capital Management LLC now owns 6,511 shares of the company’s stock worth $1,154,000 after purchasing an additional 112 shares in the last quarter. Eclectic Associates Inc. ADV boosted its position in shares of Johnson & Johnson by 2.9% during the 1st quarter. Eclectic Associates Inc. ADV now owns 9,626 shares of the company’s stock worth $1,706,000 after purchasing an additional 268 shares in the last quarter. Xponance Inc. boosted its position in shares of Johnson & Johnson by 1.3% during the 1st quarter. Xponance Inc. now owns 239,452 shares of the company’s stock worth $42,438,000 after purchasing an additional 3,047 shares in the last quarter. JGP Wealth Management LLC boosted its position in shares of Johnson & Johnson by 6.4% during the 1st quarter. JGP Wealth Management LLC now owns 63,457 shares of the company’s stock worth $11,557,000 after purchasing an additional 3,828 shares in the last quarter. Finally, BLB&B Advisors LLC boosted its position in shares of Johnson & Johnson by 0.4% during the 1st quarter. BLB&B Advisors LLC now owns 131,323 shares of the company’s stock worth $23,274,000 after purchasing an additional 486 shares in the last quarter. Institutional investors own 67.84% of the company’s stock.

About Johnson & Johnson (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.